Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Xiaoping Zou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4147-7051; OpenAlex author ID A5027664400, A5100337223. Sources: OpenAlex.

Their work

Papers
29 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2014: 2 papers · 2015: 3 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 7 papers · 2022: 2 papers · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 29

  1. A pH-responsive liposomal nanoplatform for reprogramming lactate metabolism and immunogenic activation in pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2026.124401↗
  2. ALDH1A3 promotes the lung metastatic organotropism of pancreatic ductal adenocarcinoma through semaphorin signaling. Last author DOI 10.1016/j.isci.2026.115950↗
  3. Clinical characteristics of pancreatic cancer presenting with acute pancreatitis: a propensity-matched cohort study. Co-author DOI 10.1007/s00464-025-11654-z↗
  4. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  5. CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202305279↗
  6. HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway. Last author DOI 10.1186/s12957-024-03409-2↗
  7. Integrated bioinformatics analysis identifies PCSK9 as a prognosticator correlated with lipid metabolism in pancreatic adenocarcinoma. Last author DOI 10.1186/s12957-024-03532-0↗
  8. Cinchonine-induced cell death in pancreatic cancer cells by downregulating RRP15. Co-author DOI 10.1002/cbin.11987↗
  9. Protein tyrosine phosphatase nonreceptor type 2 exerts antimetastatic functions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mc.23554↗
  10. Lithium chloride induces apoptosis by activating endoplasmic reticulum stress in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2023.101792↗
  11. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-023-40727-7↗
  12. Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations. Co-author DOI 10.1038/s41388-022-02328-4↗
  13. Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic niches to inhibit liver metastasis. Last author DOI 10.1039/d2bm00770c↗
  14. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Co-author DOI 10.1053/j.gastro.2021.07.030↗
  15. Analysis of T-cell receptor repertoire in peripheral blood of patients with pancreatic cancer and other pancreatic diseases. Co-author DOI 10.1111/jcmm.16358↗
  16. Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent man… Co-author DOI 10.1186/s13148-021-01016-6↗
  17. Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer. Co-author DOI 10.2147/cmar.s330473↗
  18. Plasma-Derived Exosomal ALIX as a Novel Biomarker for Diagnosis and Classification of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.628346↗
  19. Perineural Invasion and Associated Pain Transmission in Pancreatic Cancer. Last author DOI 10.3390/cancers13184594↗
  20. GPRC5A: An emerging prognostic biomarker for predicting malignancy of Pancreatic Cancer based on bioinformatics analysis. Last author DOI 10.7150/jca.52578↗
  21. CircRHOT1 mediated cell proliferation, apoptosis and invasion of pancreatic cancer cells by sponging miR-125a-3p. Co-author DOI 10.1111/jcmm.15572↗
  22. ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Co-author DOI 10.3389/fonc.2020.00915↗
  23. Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2018.07.003↗
  24. Inhibitory effect of baicalein combined with gemcitabine in human pancreatic cancer cell lines. First author DOI 10.3892/ol.2018.8043↗
  25. Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. Last author DOI 10.1016/j.biopha.2015.08.017↗
  26. Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway. Co-author DOI 10.1016/j.pan.2015.04.001↗
  27. The Effects of HSP27 on Gemcitabine-Resistant Pancreatic Cancer Cell Line Through Snail. Last author DOI 10.1097/mpa.0000000000000418↗
  28. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Last author DOI 10.1016/j.canlet.2014.02.012↗
  29. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells. Co-author DOI 10.1016/j.intimp.2013.12.022↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shanshan Shen · 15 shared papers, 2015–2025 · strength 1.89
  2. Ying Lv · 13 shared papers, 2014–2026 · strength 1.81
  3. Shu Zhang · 11 shared papers, 2020–2024 · strength 1.54
  4. Hongzhen Li · 6 shared papers, 2020–2026 · strength 0.89
  5. Siqi Zhou · 5 shared papers, 2021–2024 · strength 0.88
  6. Shuang Nie · 6 shared papers, 2018–2026 · strength 0.86
  7. Xuetian Qian · 5 shared papers, 2020–2026 · strength 0.80
  8. Yixuan Zhang · 6 shared papers, 2021–2023 · strength 0.78
  9. Ying Lv · 5 shared papers, 2015–2026 · strength 0.62
  10. Helmut Friess · 5 shared papers, 2018–2025 · strength 0.61
  11. Yixuan Zhang · 3 shared papers, 2022–2026 · strength 0.54
  12. Lei Wang · 4 shared papers, 2020–2023 · strength 0.46
  13. Bo Kong · 5 shared papers, 2018–2021 · strength 0.45
  14. Hao Wu · 3 shared papers, 2022–2023 · strength 0.42
  15. Hui Wang · 3 shared papers, 2021–2023 · strength 0.38
  16. Zhiheng Zhang · 3 shared papers, 2018–2025 · strength 0.32
  17. Christoph W. Michalski · 3 shared papers, 2018–2025 · strength 0.32
  18. Jorg H. Kleeff · 3 shared papers, 2018–2025 · strength 0.32
  19. Aotian Chen · 1 shared paper, 2024 · strength 0.28
  20. Zipeng Lu · 2 shared papers, 2020–2025 · strength 0.27
  21. Mingyue Hu · 2 shared papers, 2020–2025 · strength 0.27
  22. Kuirong Jiang · 2 shared papers, 2020–2025 · strength 0.27
  23. Chao Yan · 2 shared papers, 2022–2023 · strength 0.26
  24. André L. Mihaljević · 2 shared papers, 2021–2025 · strength 0.26
  25. Dongming Zhu · 2 shared papers, 2021–2023 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.